Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial (K-PASS)
This double-blinded, placebo-controlled feasibility trial (n=32) investigates the potential of a postoperative low-dose ketamine infusion to prevent depressive symptoms in neurosurgical patients with a history of depression.
Details
Randomised, double-blind, placebo-controlled, parallel-group feasibility trial at Washington University School of Medicine/Barnes-Jewish Hospital assessing whether a postoperative low-dose ketamine infusion prevents depressive symptoms in neurosurgical patients with a history of depression.
Intervention: single postoperative IV bolus of ketamine 0.5 mg/kg over 10 minutes followed by infusion 0.3 mg/kg/h for 2 hours 50 minutes; comparator: equal-volume normal saline. Primary aim is feasibility for a future phase 3 prevention trial; outcomes include depressive symptom measures and safety/tolerability.